Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study

Introduction Screening of young women is often discouraged because of the high risk of unnecessary diagnostics or overtreatment. Multiple countries therefore use cytology instead of high risk human papillomavirus (hrHPV)-testing as screening method for young women because of the limited specificity of hrHPV-testing. The objective of this study was to investigate how hrHPV screening before the age of 30, can be used to reduce the future prevalence of high-grade cervical lesions in young women. Methods We retrospectively analyzed follow-up data from a cohort study on HPV prevalence in unscreened Dutch women aged 18–29 years. Women performed multiple self-collected cervico-vaginal samples for HPV detection and genotyping. At least one valid cervical pathology result was obtained from 1,018 women. Women were categorized as hrHPV negative, cleared- or persistent hrHPV infection. Anonymized follow-up data for each group was obtained. Composite outcome measures were defined as; normal, low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). The association between prior hrHPV status and cytology and histology outcome was analyzed. Results After exclusion, a pathology result was registered for 962 women. The prevalence of HSIL was 19.3% in women with a persistent HPV infection at a younger age. This is significantly higher (p<0,001) compared with the HSIL prevalence of 1.5% in HPV-negative women, and 3.1% (n = 8) in women who cleared the hrHPV infection in the past. Conclusion Women with a persistent hrHPV infection in their 20s, show an increased prevalence of HSIL lesions in their early 30s. Screening for persistent hrHPV infections, instead of cytology screening before the age of 30, can be used to reduce the future prevalence of cervical cancer in young women.

[1]  P. Snijders,et al.  The clinical value of HPV genotyping in triage of women with high‐risk‐HPV‐positive self‐samples , 2016, International journal of cancer.

[2]  A. Jemal,et al.  Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008-2013. , 2015, Cancer epidemiology.

[3]  H. Chesson,et al.  The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States , 2014, Sexually transmitted diseases.

[4]  C. Meijer,et al.  Comparative performance of novel self‐sampling methods in detecting high‐risk human papillomavirus in 30,130 women not attending cervical screening , 2014, International journal of cancer.

[5]  W. Melchers,et al.  The current position and the future perspectives of cervical cancer screening , 2014, Expert review of anticancer therapy.

[6]  J. Berkhof,et al.  Prospective follow‐up of 2,065 young unscreened women to study human papillomavirus incidence and clearance , 2013, International journal of cancer.

[7]  R. Banzi,et al.  High‐risk HPV testing on self‐sampled versus clinician‐collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening , 2013, International journal of cancer.

[8]  M. Gissler,et al.  Loop Electrosurgical Excision Procedure and the Risk for Preterm Delivery , 2013, Obstetrics and gynecology.

[9]  M. Schiffman,et al.  2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2013, Journal of lower genital tract disease.

[10]  Diane Solomon,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[11]  L. Michala,et al.  A cross sectional study of HPV type prevalence according to age and cytology , 2013, BMC Infectious Diseases.

[12]  M. Mollers,et al.  Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. , 2013, Vaccine.

[13]  J. Berkhof,et al.  Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening , 2012, International journal of cancer.

[14]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[15]  M. Gissler,et al.  Loop Electrosurgical Excision Procedure and the Risk for Preterm Birth , 2009, Obstetrics and gynecology.

[16]  W. Quint,et al.  Sexual Behaviour and HPV Infections in 18 to 29 Year Old Women in the Pre-Vaccine Era in the Netherlands , 2008, PloS one.

[17]  Chee-Jen Chang,et al.  Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan , 2008, International journal of cancer.

[18]  M. van Ballegooijen,et al.  Does lowering the screening age for cervical cancer in The Netherlands make sense? , 2008, International journal of cancer.

[19]  S. Wacholder,et al.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.

[20]  H. Cubie,et al.  Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study , 2005, Journal of Clinical Pathology.

[21]  L. Rozendaal,et al.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996 , 2004, Journal of Clinical Pathology.

[22]  W. Melchers,et al.  Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer , 2004, Reviews in medical virology.

[23]  W. Quint,et al.  Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. , 1999, The American journal of pathology.

[24]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.